Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Free Cash Flow (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Free Cash Flow for 4 consecutive years, with -$1.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 58.21% to -$1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.7 million through Dec 2025, down 4.38% year-over-year, with the annual reading at -$10.7 million for FY2025, 4.38% down from the prior year.
  • Free Cash Flow hit -$1.0 million in Q4 2025 for Coya Therapeutics, up from -$1.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $2.1 million in Q1 2024 to a low of -$5.8 million in Q2 2025.
  • Historically, Free Cash Flow has averaged -$2.5 million across 4 years, with a median of -$2.2 million in 2022.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 155.54% in 2024 and later crashed 231.8% in 2025.
  • Year by year, Free Cash Flow stood at -$2.2 million in 2022, then decreased by 0.81% to -$2.2 million in 2023, then fell by 7.53% to -$2.4 million in 2024, then surged by 58.21% to -$1.0 million in 2025.
  • Business Quant data shows Free Cash Flow for COYA at -$1.0 million in Q4 2025, -$1.1 million in Q3 2025, and -$5.8 million in Q2 2025.